Physician profile
Linnet Rodriguez
NPI 1851895999
$2,451.88
in general payments reported to CMS, 2019-2025
15 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.42 · 2021: $29.51 · 2022: $319 · 2023: $689 · 2024: $817 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $443.90 | 2023-2025 | Stellaris, Stellaris, Envista Mx60 Iol |
| Genentech USA, INC. | $354.75 | 2023-2025 | Vabysmo, Susvimo |
| Genentech, INC. | $317.49 | 2022-2024 | Lucentis, Vabysmo |
| Regeneron Healthcare Solutions, INC. | $315.79 | 2024-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $235.60 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $224.96 | 2023-2024 | Yutiq, Iluvien |
| Dutch Ophthalmic, USA | $111.04 | 2023 | Eva, Combined Machine, Tissueblue |
| Biogen, INC. | $95.60 | 2023 | |
| Abbvie INC. | $90.03 | 2025 | |
| Alcon Vision LLC | $78.09 | 2021-2022 | |
| Astellas Pharma US INC | $56.42 | 2024-2025 | Izervay |
| Glaxosmithkline, LLC. | $44.42 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $34.57 | 2025 | |
| Sandoz INC. | $32.94 | 2024 | Cimerli |
| Eyepoint US, INC. | $16.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linnet Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.